Kemicetine (Chloramphenicol Sodium Succinate)

The drug penetrates bacterial cells and binds to the 50S ribosomal subunit, blocking the peptidyl transferase activity essential for protein synthesis. This inhibition stops bacterial growth, providing a bacteriostatic effect that can become bactericidal at higher concentrations.

The dosage of Kemicetine is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and route of administration. No fixed regimen is provided here; the prescriber sets the appropriate dose.

Safety data for chloramphenicol sodium succinate in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any potential risk to the fetus or infant.

To order Kemicetine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Kemicetine (chloramphenicol) differs from many beta‑lactam antibiotics such as ceftriaxone by inhibiting protein synthesis rather than cell‑wall synthesis. It offers broad‑spectrum coverage, including some resistant organisms, but carries a higher risk of bone‑marrow suppression, requiring careful monitoring compared with alternatives.

Kemicetine should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain sterility and potency.

Kemicetine is supplied as a sterile injection for intramuscular or intravenous administration. The preparation is reconstituted according to the label instructions and delivered by a qualified healthcare professional using aseptic technique.

The most serious risks include aplastic anemia, Gray syndrome in neonates, and severe hepatic toxicity. These adverse events are rare but can be life‑threatening, necessitating immediate discontinuation of therapy and appropriate medical intervention.

Kemicetine is contraindicated in neonates and infants due to the risk of Gray syndrome, in patients with known hypersensitivity to chloramphenicol, and in individuals with pre‑existing severe bone‑marrow suppression. Caution is also advised for pregnant or lactating women and those with significant liver or kidney disease.